• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by PainReform Ltd.

    8/26/24 8:14:39 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email
    SC 13D 1 ea0212371-13dliapure_pain.htm SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    PainReform Ltd.

    (Name of Issuer)

     

    Ordinary shares, par value NIS 0.30 per share

    (Title of Class of Securities)

     

    M77798128

    (CUSIP Number)

     

    August 22, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), (f) or (g), check the following box: ☐

     

    Note: Schedules filed in paper format should include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     

     

       

    CUSIP No. M77798128

     

    1

    NAME OR REPORTING PERSON

     

    L.I.A. Pure Capital Ltd. (1)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS

     

    WC

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ☐ 

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     
    250,000

    8

    SHARED VOTING POWER

     
    0

    9

    SOLE DISPOSITIVE POWER

     
    250,000

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    250,000

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

    ☐ 

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)


    7.20% (2)

    14

    TYPE OF REPORTING PERSON


    CO

     

    (1)Kfir Silberman is the officer, sole director, chairman of the board of directors and control shareholder of L.I.A. Pure Capital Ltd. (“Pure Capital”).

     

    (2)Based on a total of 3,468,243 ordinary shares, par value NIS 0.30, of PainReform Ltd. (the “Issuer” and the “Ordinary Shares”, respectively) outstanding as of July 9, 2024 (based on the Issuer’s proxy statement filed under its Report of Foreign Private Issuer on Form 6-K on July 9, 2024).

     

    -2-

     

      

    CUSIP No. M77798128 

     

    1

    NAME OR REPORTING PERSON

     

    Kfir Silberman (1)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS

     

    AF

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

     

    ☐ 

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    7

    SOLE VOTING POWER

     

    250,000

    8

    SHARED VOTING POWER

     

    0

    9

    SOLE DISPOSITIVE POWER

     

    250,000

    10

    SHARED DISPOSITIVE POWER

     

    0

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    250,000

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

    ☐ 

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    7.20% (2)

    14

    TYPE OF REPORTING PERSON

     

    IN

     

    (1)Kfir Silberman is the officer, sole director, chairman of the board of directors and control shareholder of Pure Capital.

     

    (2)Based on a total of 3,468,243 Ordinary Shares of the Issuer outstanding as of July 9, 2024 (based on the Issuer’s proxy statement filed under its Report of Foreign Private Issuer on Form 6-K on July 9, 2024).

     

    -3-

     

     

    Item 1(a). Name of Issuer:
       
      PainReform Ltd. (the “Issuer”)
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      65 Yigal Alon St., Tel Aviv 6744316
       
    Item 2. Identity and Background
       
     

    (a)-(c) Pure Capital is an Israeli holding company incorporated in 2010. The address of its principal office and principal place of business is 20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916, c/o Kfir Silberman. As of the date of this Schedule, Kfir Silberman, an Israeli citizen, is the officer, sole director and serves as the chairman of the board of directors of Pure Capital.

     

    Kfir Silberman is the control shareholder of Pure Capital. As of the date of this Schedule, Mr. Silberman owns 100% of the shares of Pure Capital. The address of his principal office and principal place of business is 20 Raoul Wallenberg Street, Tel Aviv, Israel 6971916.

       
      (d)-(e) During the last five years, neither Pure Capital or Kfir Silberman (collectively, the “Reporting Persons”) (i) has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.
       
     

    (f) Kfir Silberman is an Israeli citizen.

     

    The Reporting Persons have entered into a Joint Filing Agreement, dated as of August 26, 2024, a copy of which is attached hereto as Exhibit 1.

       
    Item 3. Source and Amount of Funds or Other Consideration
       
      The Ordinary Shares reported herein as beneficially owned by Pure Capital were acquired with the working capital of Pure Capital as applicable (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business).
       
    Item 4. Purpose of Transaction.
       
      The Reporting Persons have not yet formalized any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D; however, the Reporting Persons, at any time, and from time to time, may choose to sell or transfer any portion of the Ordinary Shares beneficially owned by the Reporting Persons and/or purchase any amount of additional Ordinary Shares, and/or review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management of the Issuer or the Board of Directors with respect to the business and affairs of the Issuer and may from time to time consider pursuing or proposing such matters with advisors, the Issuer, or other persons.

     

    -4-

     

     

    Item 5. Interests in Securities of the Issuer.
       
      (a)-(b) The information included herein is based on a total of 3,468,243 Ordinary Shares of the Issuer outstanding as of July 9, 2024 (based on the Issuer’s proxy statement filed under its Report of Foreign Private Issuer on Form 6-K on July 9, 2024).
       
      Pure Capital has the sole dispositive and voting power over 250,000 Ordinary Shares, representing approximately 7.20% of the outstanding share capital of the Issuer.
       
      Kfir Silberman does not directly own any Ordinary Shares. Mr. Silberman, as the owner and controlling shareholder of Pure Capital, may be deemed a beneficial owner of any Ordinary Shares beneficially owned by Pure Capital.
       
      (c) Schedule A annexed hereto lists all transactions in securities of the Issuer by the Reporting Persons during the past 60 days. All of such transactions were effected in the open market.
       
      (d) Except as set forth in Item 4 above, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares beneficially owned by the Reporting Persons.
       
      (e) N/A.
       
    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
       
      N/A.

     

    Item 7. Material to be Filed as Exhibits

     

    Exhibit 1 Joint Filing Agreement by and among L.I.A. Pure Capital Ltd. and Kfir Silberman, dated August 26, 2024

     

    -5-

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      KFIR SILBERMAN
       
      /s/ Kfir Silberman
      Kfir Silberman
       
      L.I.A. PURE CAPITAL LTD.
       
      /s/ Kfir Silberman
      Kfir Silberman
       
    Dated:  August 26, 2024  

     

    -6-

     

     

    SCHEDULE A

     

    Transactions in Securities of the Issuer Since the Filing of the Schedule 13D

     

    PAINREFORM Ltd.  

     

    Nature of the Transaction  Securities
    Purchased/
    (Sold)
       Price Per
    Security (US$)
       Date of
    Purchase/
    Sale
    Purchase of Ordinary Shares   200,000    0.28   08/22/2024
    Purchase of Ordinary Shares   50,000    0.26   08/23/2024

     

     

     

     

     

    Get the next $PRFX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PainReform Provides Business Update for the Six Months Ended June 30, 2025

    TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025. Key Highlights: Completed majority investment in LayerBio, adding OcuRing™-K, a breakthrough dropless cataract therapy targeting a ~$9B global marketAdvanced PRF-110 with ongoing R&D following partially positive efficacy signals in postoperative painExpanded DeepSolar with completion of Smart Energy Management app, acceptance into NVIDIA Connect Program, and successful completion

    10/1/25 9:27:49 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform/DeepSolar Accepted into NVIDIA Connect Program

    TEL AVIV, Israel, Aug. 19, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced that DeepSolar, PainReform's solar energy business unit developing next-generation AI-driven solar analytics, has been accepted into the prestigious NVIDIA Connect Program. This program is NVIDIA's premier development track for independent software vendors building transformative AI-based solutions across sectors. Participation in the program provides DeepSolar with access to NVIDIA's industry-leading AI frameworks, development tools, and engineering support. This future collaboration will support efforts to advance DeepSolar Predict, the company's breakthrough solar forecasting solution

    8/19/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

    TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), today announced, through its pharmaceutical division, the closing of its previously announced investment in LayerBio, Inc., a privately held Boston-based biotechnology company advancing sustained-release drug delivery technologies in ophthalmology. With this transaction, PainReform has acquired a majority equity interest in LayerBio and plans to initiate the next clinical trial of OcuRing™-K, LayerBio's lead investigational product for pain and inflammation control following cataract surgery. This transaction positions PainReform to potentially address a large and growing clinical need in the global catarac

    8/13/25 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    10/1/25 9:29:56 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/19/25 8:45:37 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PainReform Ltd.

    6-K - PAINREFORM LTD. (0001801834) (Filer)

    8/13/25 4:16:22 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care